Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: GLP-1RA, Other, Topics Apr 01 | 2026Whoop Raises Series G with Participation from Abbott; Currax Partners with Peek; Wegovy NICE Recommendation; Novo Cuts Bloomington Workforce; Ambrosia Raises Series BPurchase Blast
$599
Posted in: GLP-1RA, Topics Apr 01 | 2026Orforglipron Approved by FDA as “Foundayo”Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 31 | 2026Novo Pilots Subscription-Based Model for Wegovy; Novo Initiates Another Ph3 Zenagamtide Study; Inventiva Q4 ‘25 Earnings; Beta Bionics Launches New Data Analysis Feature; Vaxess Rebrands as Terrestrial BioPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Mar 30 | 2026Kailera Files IPO; Diamyd Data Disappoints; Insilico and Lilly Partner for AI Drug Discovery; EMA Approves Bayer’s Kerendia for HFpEF; Gan & Lee QW Insulin; Roche Ph1 CAD Study; Lilly Ph3 TOGETHER-PsA ResultsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Mar 27 | 2026Novo’s Awiqli Receives FDA Approval; Oral Wegovy Discount Price Extension; Kailera Ph2 Obesity Study; Ionis Cuts TRYNGOLZA WAC PricePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 26 | 2026Wave Crashes Following Disappointing Ph1 Obesity Data; Novo’s 2026 Annual General Meeting; Viking Completes VANQUISH-2 EnrollmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 25 | 2026Novo Triple Agonist T2DM Data; BI 2026 Annual Press Conference; Pfizer Doses First Patient in VESPER-5; Merck Acquires Terns; Fractyl Q4 ’25 Earnings; Biomea FY 2025 Updates; BrightGene Ph1 Dual Agonist DataPurchase Blast
$599
Posted in: Other, Topics Mar 24 | 2026Zealand Establishes Boston Research Hub; Aardvark Pipeline on Hold; Rezolute Shares CHI Program Updates; Rivus New MASH TrialPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Other, Topics Mar 23 | 2026Novo Initiates Ph1 Oral ASCL5 Inhibitor Study for Obesity; FDA to Host Public Feedback Meeting on CNPV; March CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 20 | 2026Novo Initiates Ph3 Zenagamtide Obesity and Knee OA Study; Biohaven Completes Enrollment in its Ph2b Obesity StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Topics Mar 19 | 2026Retatrutide T2DM Data Continue to Impress; FDA Approves Novo’s High Dose SemaPurchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery, Other, Topics Mar 18 | 2026MiniMed Flex Receives FDA Clearance; MetaVia Advances DA-1726 in Obesity; Ascletis Selects Another Obesity CandidatePurchase Blast
$599
Posted in: GLP-1RA, Topics Mar 16 | 2026Structure’s Topline Ph2 Aleniglipron Data; Lilly Launches Zepbound KwikPen; Positive Topline Ph3 Finerenone FIND-CKD ResultsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Mar 13 | 2026ATTD 2026 Key Press Releases (March 13)Purchase Blast
$599
Posted in: Basal Insulin, Other, Topics Mar 13 | 2026ATTD 2026 Key Press Releases (March 12)Purchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 12 | 2026ATTD 2026 Key Press Releases (March 11)Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Mar 10 | 2026Kailera Initiates Another Ph2 Ribupatide Study; Ascletis Reports Topline Ph2 Data; Laekna Announces Topline Ph1 Data; Glooko Connects with Roche’s CGM; SK pharmteco to Manufacture Long-Acting API for Current Lilly Product; Novo Acknowledges FDA Form 483Purchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 09 | 2026Novo and Hims Take Another Turn at a Partnership; AbbVie Reports Topline Ph1 Amylin Data; Regeneron & Hansoh Share Ph3 Olatorepatide China Results; Lilly Releases Statement on CMS Obesity BALANCE Model; Zepbound KwikPen Available on Amazon; Veru Enrolls First Patient in Ph2b PLATEAU Study; Sequel Expands AID Launch Purchase Blast
$599
Posted in: Other, Topics Mar 09 | 2026Thoughts on Ph2 ZUPREME-1 Data: Can Petrelintide Still Compete?Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 06 | 2026MiniMed Shares IPO Pricing; NMPA Approves Sciwind/Pfizer’s Ecnoglutide Injection in Obesity; Novo Appoints New SVPPurchase Blast